المؤلفون: A. N. Polyakov, D. A. Granov, Yu. I. Patyutko, I. A. Pokataev, A. A. Polikarpov, T. I. Kagacheva, I. S. Bazin, A. Sh. Umirzokov, D. Yu. Frantsev, V. N. Zhuikov, D. V. Podluzhny, А. Н. Поляков, Д. А. Гранов, Ю. И. Патютко, И. A. Покатаев, А. А. Поликарпов, Т. И. Кагачева, И. С. Базин, А. Ш. Умирзоков, Д. Ю. Францев, В. Н. Жуйков, Д. В. Подлужный

المصدر: Research and Practical Medicine Journal; Том 10, № 1 (2023); 57-67 ; Research'n Practical Medicine Journal; Том 10, № 1 (2023); 57-67 ; 2410-1893 ; 10.17709/2410-1893-2023-10-1

مصطلحات موضوعية: факторы неблагоприятного прогноза, combination therapy, preoperative chemotherapy, transarterial chemoembolization, hepatic artery infusion chemotherapy, post‑resection liver failure, poor prognostic factors, комбинированное лечение, предоперационная химиотерапия, химиоэмболизация печеночной артерии, химиоинфузия печеночной артерии, пострезекционная печеночная недостаточность

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/860/538Test; https://www.rpmj.ru/rpmj/article/view/860/546Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/707Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/708Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/709Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/710Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/860/711Test; Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al.; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019 May;20(5):663–673. https://doi.org/10.1016/s1470Test‑2045(18)30915‑x Erratum in: Lancet Oncol. 2019 Apr 2.; Yadav S, Xie H, Bin‑Riaz I, Sharma P, Durani U, Goyal G, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: propensity score matched analysis. Eur J Surg Oncol. 2019 Aug;45(8):1432–1438. https://doi.org/10.1016/j.ejso.2019.03.023Test; Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA Surg. 2020 Sep 1;155(9):823–831. https://doi.org/10.1001/jamasurg.2020.1973Test; Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 2021;27:100354. https://doi.org/10.1016/j.ctarc.2021.100354Test; Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018 Jun;105(7):848–856. https://doi.org/10.1002/bjs.10676Test; Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al.; ABC‑02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273–1281. https://doi.org/10.1056/nejmoa0908721Test; Rizzo A, Brandi G. First‑line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC‑02 Trial: “And Yet It Moves!”. Cancer Treat Res Commun. 2021;27:100335. https://doi.org/10.1016/j.ctarc.2021.100335Test; Cho Y, Kim TH, Seong J. Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma. Strahlenther Onkol. 2017 Aug;193(8):620–629. https://doi.org/10.1007/s00066Test‑017‑1128‑7; Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single‑center study. Ann Surg Oncol. 2013 Jan;20(1):318–324. https://doi.org/10.1245/s10434Test‑012‑2312‑8; Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, Cisplatin, and nab‑Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 1;5(6):824–830. https://doi.org/10.1001/jamaoncol.2019.0270Test; Ray CE Jr, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, et al. Metaanalysis of survival, complications, and imaging response following chemotherapy‑based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013 Aug;24(8):1218–1226. https://doi.org/10.1016/j.jvir.2013.03.019Test; Holster JJ, El Hassnaoui M, Franssen S, IJzermans JNM, de Jonge J, Mostert B, et al. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta‑Analysis. Ann Surg Oncol. 2022 Sep;29(9):5528–5538. https://doi.org/10.1245/s10434Test‑022‑11439‑x; https://www.rpmj.ru/rpmj/article/view/860Test

الإتاحة: https://doi.org/10.17709/2410-1893-2023-10-1-5Test
https://doi.org/10.17709/2410-1893-2023-10-1Test
https://doi.org/10.1016/s1470Test‑2045(18)30915‑x
https://doi.org/10.1016/j.ejso.2019.03.023Test
https://doi.org/10.1001/jamasurg.2020.1973Test
https://doi.org/10.1016/j.ctarc.2021.100354Test
https://doi.org/10.1002/bjs.10676Test
https://doi.org/10.1056/nejmoa0908721Test
https://doi.org/10.1016/j.ctarc.2021.100335Test
https://doi.org/10.1007/s00066Test‑017‑1128‑7

المؤلفون: A. N. Polyakov, Yu. I. Patyutko, I. V. Pogrebnyakov, B. I. Dolgushin, V. N. Sholohov, O. S. Vlasenko, I. S. Bazin, D. M. Kantieva, K. A. Romanova, V. A. Kozhushkov, I. A. Kozhushkov, D. V. Podluzhnyi, А. Н. Поляков, Ю. И. Патютко, И. В. Погребняков, Б. И. Долгушин, В. Н. Шолохов, О. С. Власeнко, И. С. Базин, Д. М. Кантиева, К. А. Романова, В. А. Кожушков, И. А. Кожушков, Д. В. Подлужный

المساهمون: The consumables for electroporation were provided by REEPL., Расходные материалы для электропорации предоставлены фирмой REEPL («РИПЛ»).

المصدر: Pelvic Surgery and Oncology; Том 13, № 1 (2023); 45-53 ; Тазовая хирургия и онкология; Том 13, № 1 (2023); 45-53 ; 2686-7435

مصطلحات موضوعية: необратимая электропорация, methods of local tumor destruction, combined therapy, flat-detector computed tomography, irreversible electroporation, методы локальной деструкции опухоли, комбинированная терапия, плоскодетекторная компьютерная томография

وصف الملف: application/pdf

العلاقة: https://ok.abvpress.ru/jour/article/view/596/414Test; Heestand G.M., Murphy J.D., Lowy A.M. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol 2015;1;33(16):1770–8. PMID: 25918279. DOI:10.1200/JCO.2014.59.7930; Suker M., Beumer B.R., Sadot E. et al. Folfirinox for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016;17:801–10. PMID: 27160474. DOI:10.1016/S1470-2045(16)00172-8; Narayanan G., Daye D., Wilson N.M. et al. Ablation in Pancreatic Cancer: Past, Present and Future. Cancers (Basel) 2021;13(11):2511. PMID: 34063784. DOI:10.3390/cancers13112511; Edd J.F., Horowitz L., Davalos R.V. et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006;53(7):1409–15. PMID: 16830945. DOI:10.1109/TBME.2006.873745; Narayanan G., Hosein P.J., Arora G. et al. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 2012;23(12):1613–21. PMID: 23177107. DOI:10.1016/j.jvir.2012.09.012; Saad A.M., Turk T., Al-Husseini M.J., Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018;18(1):688. PMID: 29940910. DOI:10.1186/s12885-018-4610-4; Balaban E.P., Mangu P.B., Khorana A.A. et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(22):2654–68. PMID: 27247216. DOI:10.1200/JCO.2016.67.5561; Spiliopoulos S., Zurlo M.T., Casella A. et al. Current status of non-surgical treatment of locally advanced pancreatic cancer. World J Gastrointest Oncol 2021;13(12):2064–75. PMID: 35070042. DOI:10.4251/wjgo.v13.i12.2064; Hammel P., Huguet F., van Laethem J.L. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016;315(17): 1844–53. PMID: 27139057. DOI:10.1001/jama.2016.4324; Herman J.M., Chang D.T., Goodman K.A. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121(7):1128–37. PMID: 25538019. DOI:10.1002/cncr.29161; Reyngold M., O’Reilly E.M., Varghese A.M. et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 2021;7(5):735–8. PMID: 33704353. DOI:10.1001/jamaoncol.2021.0057; Zeng X.L., Wang H.H., Meng M.B. et al. Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. Onco Targets Ther 2016;9:3985–92. PMID: 27418841. DOI:10.2147/OTT.S102784; Al-Sakere B., Andre F., Bernat C. et al. Tumor ablation with irreversible electroporation. PloSone 2007;2(11):e1135. PMID: 17989772. DOI:10.1371/journal.pone.0001135; Edelblute C.M., Hornef J., Burcus N.I. et al. Controllable Moderate Heating Enhances the Therapeutic Efficacy of Irreversible Electroporation for Pancreatic Cancer. Sci Rep 2017;7(1): 11767. PMID: 28924200. DOI:10.1038/s41598-017-12227-4; Москвичева Л.И., Петров Л.О., Сидоров Д.В. Возможности современных методов абляции при нерезектабельном местнораспространенном раке поджелудочной железы. Исследования и практика в медицине 2018;5(2):86–99. DOI:10.17709/2409-2231-2018-5-2-10; Wendler J.J., Fischbach K., Ricke J. et al. Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol 2016;81:54–64. PMID: 26966472. DOI:10.12659/PJR.896034; Martin R.C. 2nd , Kwon D., Chalikonda S. et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg 2015;262(3):486–94. PMID: 26258317. DOI:10.1097/SLA.0000000000001441; Vogel J.A., Rombouts S.J., de Rooij T. et al. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann Surg Oncol 2017;24(9):2734–43. PMID: 28560601. DOI:10.1245/s10434-017-5900-9; Астахов Д.А., Панченков Д.Н., Иванов Ю.В и др. Необратимая электропорация при местно-распространенном раке поджелудочной железы. Анналы хирургической гепатологии 2018;23(2):59–68. DOI:10.16931/1995-5464.2018259-68; Ruarus A.H., Vroomen L.G.P.H., Geboers B. et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology 2020;294(1):212–20. PMID: 31687922. DOI:10.1148/radiol.2019191109; Yang P.C., Huang K.W., Pua U. et al. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer – A multi-institutional clinical study in Asia. Eur J Surg Oncol 2020;46(5):811–7. PMID: 31839436. DOI:10.1016/j.ejso.2019.12.006; Mansson C., Brahmstaedt R., Nilsson A. et al. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol 2016;42(9):1401–6. PMID: 26906114. DOI:10.1016/j.ejso.2016.01.024; Lafranceschina S., Brunetti O., Delvecchio A. et al. Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers (Basel) 2019;11(11):1718. PMID: 31684186. DOI:10.3390/cancers11111718; Moris D., Machairas N., Tsilimigras D.I. et al. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. Ann Surg Oncol 2019;26(6):1657–68. PMID: 30843163. DOI:10.1245/s10434-019-07261-7; https://ok.abvpress.ru/jour/article/view/596Test

الإتاحة: https://doi.org/10.17650/2686-9594-2023-13-1-45-53Test
https://doi.org/10.1200/JCO.2014.59.7930Test
https://doi.org/10.1016/S1470-2045Test(16)00172-8
https://doi.org/10.3390/cancers13112511Test
https://doi.org/10.1109/TBME.2006.873745Test
https://doi.org/10.1016/j.jvir.2012.09.012Test
https://doi.org/10.1186/s12885-018-4610-4Test
https://doi.org/10.1200/JCO.2016.67.5561Test
https://doi.org/10.4251/wjgo.v13.i12.2064Test
https://doi.org/10.1001/jama.2016.4324Test

المؤلفون: L. M. Dyakov, O. M. Krivtsova, P. A. Khesina, I. F. Kustova, N. A. Dyakova, N. S. Muge, N. E. Kudashkin, Yu. I. Patyutko, N. L. Lazarevich, Л. М. Дьяков, О. М. Кривцова, П. А. Хесина, И. Ф. Кустова, Н. А. Дьякова, Н. С. Мюге, Н. Е. Кудашкин, Ю. И. Патютко, Н. Л. Лазаревич

المساهمون: The work was carried out with the financial support of the Russian Foundation for Basic Research (grant No. 18-29-09164)., Работа выполнена при финансовой поддержке Российского фонда научных исследований (грант № 18-29-09164).

المصدر: Advances in Molecular Oncology; Том 9, № 3 (2022); 24-37 ; Успехи молекулярной онкологии; Том 9, № 3 (2022); 24-37 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2022-9-3

مصطلحات موضوعية: жидкостная биопсия, circulating DNA, somatic mutations, liquid biopsy, циркулирующая ДНК, соматические мутации

وصف الملف: application/pdf

العلاقة: https://umo.abvpress.ru/jour/article/view/457/269Test; Siravegna G., Marsoni S., Siena S., Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14(9):531-48. DOI:10.1038/nrclinonc.2017.14; Wan J.C.M., Massie C., Garcia-Corbacho J. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17(4):223-38. DOI:10.1038/nrc.2017.7; Cescon D.W., Bratman S.V., Chan S.M., Siu L.L. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer 2020;1(3):276-90. DOI:10.1038/s43018-020-0043-5; Kilgour E., Rothwell D.G., Brady G., Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 2020;37(4):485-95. DOI:10.1016/j.ccell.2020.03.012; Cisneros-Villanueva M., Hidalgo-Perez L., Rios-Romero M. et al. Cell-free DNA analysis in current cancer clinical trials: a review. Br J Cancer 2022;126(3):391-400. DOI:10.1038/s41416-021-01696-0; Keppens C., Palma J.F., Das P.M. Detection of EGFR variants in plasma: a multilaboratory comparison of a Real-Time PCR EGFR Mutation test in Europe. J Mol Diagn 2018;20(4):483-94. DOI:10.1016/j.jmoldx.2018.03.006; Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3): 209-49. DOI:10.3322/caac.21660; Llovet J.M., Zucman-Rossi J., Pikarsky E. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018. DOI:10.1038/nrdp.2016.18; Zucman-Rossi J., Villanueva A., Nault J.C. et al. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149(5):1226-39. PMID: 26099527. DOI:10.1053/j.gastro.2015.05.061.; Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 2017;169(7):1327-41. DOI:10.1016/j.cell.2017.05.046; Кустова И.Ф., Макарова А.С., Лазаревич Н.Л. Потенциал использования биомаркеров метилирования для диагностики и прогноза гепатоцеллюлярной карциномы методом жидкостной биопсии. Успехи молекулярной онкологии 2018;5(4):8-19. DOI:10.17650/2313-805X-2018; Tran N.H., Kisiel J., Roberts L.R. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3(4):100304. DOI:10.1016/j.jhepr.2021.100304; Thorvaldsdottir H., Robinson J.T., Mesirov J.P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14(2):178-92. DOI:10.1093/bib/bbs017; Liu J., Huang Sh., Sun M. et al. An improved allele-specific PCR primer design method for SNP marker analysis and its application. Plant Methods 2012;8(1):34. DOI:10.1186/17464811-8-34; Ng C.K.Y., Di Costanzo G.G., Terracciano L.M., Piscuoglio S. Circulating cell-free DNA in hepatocellular carcinoma: current insights and outlook. Front Med (Lausanne) 2018;5:78. DOI:10.3389/fmed.2018.00078; Labgaa I., Villacorta-Martin C., D'Avola D. et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018;37:3740-52. DOI:10.1038/s41388-018-0206-3; Bratman S.V., Yang S.Y.C., Iafolla M.A.J. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembro-lizumab. Nat Cancer 2020;1(9):873-81. DOI:10.1038/s43018-020-0096-5; Ikeda S., Tsigelny I., Skjevik A. et al. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. The Oncologist 2018;23(5):586-93. DOI:10.1634/theoncologist.2017-0479; https://umo.abvpress.ru/jour/article/view/457Test

الإتاحة: https://doi.org/10.17650/2313-805X-2022-9-3-24-37Test
https://doi.org/10.17650/2313-805X-2022-9-3Test
https://doi.org/10.1038/nrclinonc.2017.14Test
https://doi.org/10.1038/nrc.2017.7Test
https://doi.org/10.1038/s43018-020-0043-5Test
https://doi.org/10.1016/j.ccell.2020.03.012Test
https://doi.org/10.1038/s41416-021-01696-0Test
https://doi.org/10.1016/j.jmoldx.2018.03.006Test
https://doi.org/10.3322/caac.21660Test
https://doi.org/10.1038/nrdp.2016.18Test

المؤلفون: A. N. Polyakov, D. V. Podluzhnyi, N. E. Kudashkin, I. S. Bazin, B. M. Medvedeva, A. Yu. Syskova, D. M. Kantieva, Yu. I. Patyutko, А. Н. Поляков, Д. В. Подлужный, Н. Е. Кудашкин, И. С. Базин, Б. М. Медведева, А. Ю. Сыскова, Д. М. Кантиева, Ю. И. Патютко

المصدر: Research and Practical Medicine Journal; Том 9, № 4 (2022); 114-122 ; Research'n Practical Medicine Journal; Том 9, № 4 (2022); 114-122 ; 2410-1893 ; 10.17709/2410-1893-2022-9-4

مصطلحات موضوعية: комбинированное лечение рака поджелудочной железы, ductal adenocarcinoma, local relapse of pancreatic cancer, irreversible electroporation, combined treatment for pancreatic cancer, протоковая аденокарцинома, локальный рецидив рака поджелудочной железы, необратимая электропорация

وصف الملف: application/pdf

العلاقة: https://www.rpmj.ru/rpmj/article/view/838/517Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/692Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/693Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/694Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/695Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/696Test; https://www.rpmj.ru/rpmj/article/downloadSuppFile/838/697Test; Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492Test; Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1;34(22):2654–2668. https://doi.org/10.1200/JCO.2016.67.5561Test; Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol. Clin. Oncol. 2016;4:315– 325. https://doi.org/10.3892/mco.2015.716Test; Vogel JA, van Veldhuisen E, Agnass P, Crezee J, Dijk F, Verheij J, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: a systematic review of experimental studies. PLoS ONE. 2016;11(11):e0166987. https://doi.org/10.1371/journal.pone.0166987Test; Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy. Ann Surg 2015;262:486–494. https://doi.org/10.1097/SLA.0000000000001441Test; Астахов Д. А., Панченков Д. Н., Иванов Ю. В., Шабловский О. Р., Кедрова А. Г., Соловьев Н. А. и др. Необратимая электропорация при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):59–68. https://doi.org/10.16931/1995-5464.2018259-68Test; Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013;369:1691–1703. https://doi.org/10.1056/NEJMoa1304369Test; Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer N Engl J Med 2011;364:1817–1825. https://doi.org/10.1056/NEJMoa1011923Test; Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. https://doi.org/10.1177/1758835919850367Test; Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324Test; Ионкин Д. А., Карельская Н. А., Степанова Ю. А., Земсков В. М., Козлова М. Н., Жаворонкова О. А. и др. Криодеструкция при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):37–49. https://doi.org/10.16931/1995-5464.2018237-49Test; Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Transactions on Bio-medical Engineering 2006;53:1409–1415. https://doi.org/10.1109/TBME.2006.873745Test; Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, et al. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 2012;23:1613–1621. https://doi.org/10.1016/j.jvir.2012.09.012Test; https://www.rpmj.ru/rpmj/article/view/838Test

الإتاحة: https://doi.org/10.17709/2410-1893-2022-9-4-11Test
https://doi.org/10.17709/2410-1893-2022-9-4Test
https://doi.org/10.3322/caac.21492Test
https://doi.org/10.1200/JCO.2016.67.5561Test
https://doi.org/10.3892/mco.2015.716Test
https://doi.org/10.1371/journal.pone.0166987Test
https://doi.org/10.1097/SLA.0000000000001441Test
https://doi.org/10.16931/1995-5464.2018259-68Test
https://doi.org/10.1056/NEJMoa1304369Test
https://doi.org/10.1056/NEJMoa1011923Test

المؤلفون: Yu. I. Patyutko, N. E. Kudashkin, Ю. И. Патютко, Н. Е. Кудашкин

المصدر: Malignant tumours; № 4s1 (2016); 46-47 ; Злокачественные опухоли; № 4s1 (2016); 46-47 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: BCLC B, хирургическое лечение

وصف الملف: application/pdf

العلاقة: https://www.malignanttumors.org/jour/article/view/285/255Test; Bruix J., Sherman M. Management of hepatocellurar carcinoma: an apdate. Hepatology. 2011: 53(3): 1020–1022.; Guy J., Kelley R. K., Roberts J. et al. Multidisciplinary management of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2012; 10: 354–362.; Guglielmi A., Ruzzenente A., Conci S., Valdegamberi A., Vitali M., Bertuzzo F., De Angelis M., Mantovani G., Iacono C. Hepatocellular carcinoma: surgical perspectives beyond the barcelona clinic liver cancer recommendations. World J. Gastroenterol. 2014; 20: 7525–7533.; Forner A., Gilabert M., Bruix J., Raoul J. L. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin. Oncol. 2014; 11: 525–535.; Clavien P. A., Lesurtel M., Bossuyt P. M. et al. OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012; 13(1):11–22.; Патютко Ю. И., Котельников А. Г., Сагайдак И. В., Кудашкин Н. Е., Гахраманов А. Д., Мороз Е. А., Чай И. Хирургическое лечение гепатоцеллюлярного на фоне цирроза печени. Российский онкологический журнал. 2014. Т. 19. № 4. С. 39–40.; Poon R. T., Fan S. T., Lo C. M., Liu C. L., Lam C. M., Yuen W. K., Yeung C., Wong J. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann. Surg. 2002; 236: 602–611.; Lin C. T., Hsu K. F., Chen T. W., Yu J. C., Chan D. C., Yu C. Y., Hsieh T. Y., Fan H. L., Kuo S. M., Chung K. P., Hsieh C. B. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J. Surg. 2010 Sep; 34(9): 2155–2161.; Zhong J. H., Xiang B. D., Gong W. F., Ke Y., Mo Q. G., Ma L., Liu X., Li L. Q. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 2013; 8: 681–693.; Zhong J. H., Ke Y., Gong W. F., Xiang B. D., Ma L., Ye X. P., Peng T., Xie G. S., Li L. Q. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 2014; 260: 329–340.; Santambrogio R., Kluger M. D., Costa M., Belli A., Barabino M., Laurent A., Opocher E., Azoulay D., Cherqui D. Hepatic resection for hepatocellular carcinoma in patients with Child- Pugh’s A cirrhosis: is clinical evidence of portal hypertension a contraindication? HPB (Oxford) 2013; 15: 78–84.; He W., Zeng Q., Zheng Y., Chen M., Shen J., Qiu J., Chen M., Zou R., Liao Y., Li Q., Wu X., Li B., Yuan Y. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015; 15: 263.; https://www.malignanttumors.org/jour/article/view/285Test; undefined

الإتاحة: https://www.malignanttumors.org/jour/article/view/285Test

المؤلفون: Yu. I. Patyutko, N. Ye. Kudashkin, A. G. Kotelnikov, Ю. И. Патютко, Н. Е. Кудашкин, А. Г. Котельников

المصدر: Pelvic Surgery and Oncology; № 2 (2014); 28-32 ; Тазовая хирургия и онкология; № 2 (2014); 28-32 ; 2686-7435 ; 10.17650/2220-3478-2014-0-2

مصطلحات موضوعية: отдаленная выживаемость, pancreaticoduodenectomy, long-term survival, гастропанкреатодуоденальная резекция

وصف الملف: application/pdf

العلاقة: https://ok.abvpress.ru/jour/article/view/35/30Test; Staniunas R. J., Schoetz D. J. Extended resection for carcinoma of the colon and rectum. Surg Clin North Am 1993;73:117–29.; Koea J. B., Conlon K., Paty P. B. et al. Pancreatic or duodenal resection or both for advanced carcinoma on the right colon: is it justified? Dis Colon Rectum 2000;43:460–5.; Kaapor S., Das B., Pal S. et al. En bloc resection of right-sided colonic adenocarcinoma with adjacent organ invasion. Int J Colorectal Dis 2006;21:265–8.; Charnsangavej C., Whitley N. O. Metastases to the pancreas and peripancreatic lymph nodes from carcinoma of the right side of the colon: CT findings in 12 patients. AJR Am J Roentgenol 1993;160:49–52.; Lee W.-S., Lee W. Y., Chun H.-K. et al. En bloc resection for right colon cancer directly invading duodenum or pancreatic head. Yonsei Med J 2009;50(6):803–6.; Polk H. C. Jr. Extended resection for selected adenocarcinomas of the large bowel. Ann Surg 1972;175(6):892–9.; Davies G. C., Ellis H. Radical surgery in locally advanced cancer of the large bowel. Clin Oncol 1975;1(1):21–6.; Costa S. R., Henriques A. C., Horta S. H. et al. En-bloc pancreatoduodenectomy and right hemicolectomy for treating locally advanced right colon cancer (T4): a series of five patients. Arq Gastroenterol 2009 Apr-Jun;46(2):151–3.; Cameron J. L., Riall T. S., Coleman J. et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10–5.; Gouma D. J., van Geenen R. C., van Gulik T. M. et al. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232:786–95.; Fathy O., Abdel-Wahab M., Elghwalby N. et al. Surgical management of periampullary tumors: a retrospective study. Hepatogastroenterology 2008;55(85):1463–9.; Perez R. O., Coser R. B., Kiss D. R. et al. Combined resection of the duodenum and pancreas for locally advanced colon cancer. Curr Surg 2005;62(6):613–7.; Hunter J. A., Ryan J. A., Schultz P. En bloc resection of colon cancer adherent to other organs. Am J Surg 1987;154:67–71.; McGlone T.P., Bemie W. A., Elliot D. W. Survival following extended operations for extracolonic invasion by colon cancer. Arch Surg 1982;117:595–9.; Щепотин И. Б., Колесник Е. А., Лукашенко А. В. и др. Мультивисцеральные резекции при местно-распространенном раке ободочной кишки с инвазией в органы гепатопанкреатодуоденальной зоны. Клиническая онкология 2013;3(11):1–5.; Saiura A., Yamamoto J., Ueno M. et al. Long-term survival in patients with locally advanced colon cancer after en bloc pancreaticoduodenectomy and colectomy. Dis Colon Rectum 2008;51:1548–51.; https://ok.abvpress.ru/jour/article/view/35Test

الإتاحة: https://doi.org/10.17650/2220-3478-2014-0-2-28-32Test
https://doi.org/10.17650/2220-3478-2014-0-2Test
https://ok.abvpress.ru/jour/article/view/35Test

المؤلفون: П. Е. Тулин, М. Б. Долгушин, А. А. Оджарова, М. А. Меньков, Б. М. Медведева, С. В. Ширяев, Ю. И. Патютко, Б. И. Долгушин, P. E. Tulin, M. B. Dolgushin, A. A. Odzharova, M. A. Menkov, B. M. Medvedeva, S. V. Shiryaev, Yu. I. Patyutko, B. I. Dolgushin

المصدر: Diagnostic radiology and radiotherapy ; Лучевая диагностика и терапия

مصطلحات موضوعية: PET, 18F-FDG, 18F-FCho, computed tomography, perfusion, liver tumors, hepatocellular carcinoma, ПЭТ, 18F-ФДГ, 18F-ФХ, компьютерная томография, перфузия, опухоли печени, гепатоцеллюлярный рак

العلاقة: https://openrepository.ru/article?id=387728Test

الإتاحة: https://doi.org/10.22328/2079-5343-2015-3-59-69Test
https://openrepository.ru/article?id=387728Test